Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.05 - Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis
00:00 - 00:00 | Presenter: David C. Qian
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading...
-
+
P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P83.02 - Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study
00:00 - 00:00 | Presenter: Suresh S. Ramalingam
- Abstract
Loading...
-
+
MA01 - Novel Systemic Treatment in NSCLC
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
MA01.09 - Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)
12:15 - 12:20 | Presenter: Saad A. Khan
- Abstract
Loading...
-
+
OA04 - New Data from Rare EGFR Alterations
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
-
+
OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
11:45 - 11:55 | Presenter: Caicun Zhou
- Abstract
Loading...
-
+
PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS01.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer
07:50 - 08:00 | Presenter: Bob T. Li
- Abstract
Loading...
-
+
PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS02.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer
18:50 - 19:00 | Presenter: Bob T. Li
- Abstract
Loading...